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Y-receptors control energy homeostasis, but the role
of Npy6 receptors (Npy6r) is largely unknown. Young
Npy6r-deficient (Npy6r/) mice have reduced body
weight, lean mass, and adiposity, while older and
high-fat-fed Npy6r/ mice have low lean mass with
increased adiposity. Npy6r/mice showed reduced
hypothalamic growth hormone releasing hormone
(Ghrh) expression and serum insulin-like growth fac-
tor-1 (IGF-1) levels relative to WT. This is likely due to
impaired vasoactive intestinal peptide (VIP) signaling
in the suprachiasmatic nucleus (SCN), where we
found Npy6r coexpressed in VIP neurons. Peripheral
administration of pancreatic polypeptide (PP)
increased Fos expression in the SCN, increased en-
ergy expenditure, and reduced food intake in WT,
but not Npy6r/, mice. Moreover, intraperitoneal
(i.p.) PP injection increased hypothalamic Ghrh
mRNA expression and serum IGF-1 levels in WT,
but notNpy6r/, mice, an effect blocked by intracer-
ebroventricular (i.c.v.) Vasoactive Intestinal Peptide
(VPAC) receptors antagonism. Thus, PP-initiated
signaling through Npy6r in VIP neurons regulates
the growth hormone axis and body composition.
INTRODUCTION
Hypothalamic circuitries are important in receiving and integrating
information from other brain areas aswell as the periphery to con-
trol appetite and energy homeostasis (Sainsbury et al., 2002a).
Among the many systems involved that influence orexigenic and
anorexigenic processes in the hypothalamus, the neuropeptide
Y (NPY) system is unique in that its major neuronal component,
NPY, stimulates appetite and reduces energy expenditure,
whereas its other family members, peptide YY (PYY) and pancre-58 Cell Metabolism 19, 58–72, January 7, 2014 ª2014 Elsevier Inc.atic polypeptide (PP), which are mainly produced by endocrine
cells in theperiphery in response to food intake, act in anopposing
fashion as satiety factors (Nguyen et al., 2011; Zhang et al., 2011).
All three peptides are able to signal through a set of five known
Y-receptors (Npy1r, Npy2r, Ppyr1, Npy5r, and Npy6r) for which
they have different affinities (Nguyen et al., 2011; Zhang et al.,
2011). It has now been well established through work with trans-
genic and knockout mouse models that Npy1r and Npy5r are
mostly responsible for the appetite-stimulatory and energy-
expenditure-relatedaspectsofNPYsignaling in thehypothalamus
(Nguyen et al., 2012), whereas theNpy2r and Ppyr1 are more crit-
ical formediating satiety andother relatedaspects (Lin et al., 2009;
Sainsbury et al., 2002b; Shi et al., 2010; Zhang et al., 2010). How-
ever, despite the large amount of work being dedicated to unrav-
eling functions of the NPY system in the regulation of energy
homeostasis, no information is available for the role of the Npy6r.
The Npy6r gene is less conserved than the other Y-receptors.
It exists only as a truncated version in primate species, including
humans (Gregor et al., 1996; Matsumoto et al., 1996; Rose et al.,
1997), and it is absent from the rat genome (Burkhoff et al., 1998).
The human Npy6r gene is located on chromosome 5q31 (Gregor
et al., 1996) and contains a single-base deletion resulting in a
frameshift mutation and an early stop codon (Gregor et al.,
1996; Matsumoto et al., 1996; Rose et al., 1997). Interestingly,
an alternative splice variant of the Npy1r has been discovered
in the mouse leading to a truncated isoform of the protein similar
to the humanNpy6r (Nakamura et al., 1995), suggesting a poten-
tial for altered signaling capacity by Npy1r. Importantly, mRNA
for the truncated Npy1r and the Npy6r is produced in consider-
able amounts, and in the case of the humanNpy6r, mRNA is pro-
duced in the heart, skeletal muscle, gastrointestinal tissues, and
adrenal glands as well as in the brain (Burkhoff et al., 1998;
Gregor et al., 1996; Matsumoto et al., 1996), raising questions
as to its possible function.
In contrast to humans, primates, and rats, the Npy6r gene is
present in a nontruncated form in mice and rabbits (Burkhoff
et al., 1998; Matsumoto et al., 1996). In the mouse, Npy6r is ex-
pressed in the developing embryo, skeletal muscle, kidney, and
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tantly, in situ hybridization confirmed Npy6r expression in the
mouse hypothalamus (Weinberg et al., 1996), suggesting a role
for this receptor in the regulation of energy homeostasis. Contro-
versy surrounds the pharmacological profile of the Npy6r, with
some studies claiming an Npy1r-like profile (Weinberg et al.,
1996), others indicating a Ppyr1-like profile (Gregor et al.,
1996), and a further study describing a unique pharmacological
profile of Npy6r distinct from all the other Y receptors (Mullins
et al., 2000). This lack of consistent results arising from previous
in vitro studies makes it difficult to ascertain the true pharma-
cology and potential physiological role of Npy6r.
Considering that mice are frequently used to determine the
functional role of individual Y receptors, as well as the possibility
that manipulation of the NPY system could be used for the devel-
opmentof new therapeutics for the treatment of obesity, diabetes,
and relateddisorders, it is important toevaluate thecontributionof
all Y-receptors to the regulation of energy homeostasis, including
Npy6r in the mouse. Therefore, in this study we investigated the
metabolic characteristics and hypothalamic circuits activated by
Npy6r signaling using Npy6r knockout mice (Npy6r/). To gain
further insights into the critical physiological functions of Npy6r
in mice, we also used our Npy6r/ mouse model to determine
the physiological ligand for this Y-receptor in vivo.
RESULTS
Npy6r–/– Mice Are Viable and Have Normal Fertility
Npy6rgenedeletionwasachievedby inserting a lacZ-IRES-neoR
selection cassette into the coding frame of the Npy6r gene,
allowing for identification of normal sites of gene expression via
X-gal staining for b-galactosidase (Figure 1A). Npy6r/ mice
were identified by PCR (Figure 1B) and confirmed by RT-PCR
in various tissues (Figure 1C). Utilizing the introduced lacZ
gene, we investigated the expression pattern ofNpy6r in a variety
of peripheral tissues and throughout the brain (see Figures S1
and S2 online). Only a subset of neurons within the hypothalamic
supracharismatic nucleus (SCN) showed staining for b-gal, with
no staining in any other area of the brain or the peripheral tissues
examined, except testes. This demonstrates thatNpy6r signaling
in the brain is restricted to the SCN.
Npy6r/ mice are viable; however, they are smaller than their
wild-type (WT) counterparts (Figure 1D). Breeding of heterozy-
gous Npy6r+/mice resulted in live offspring with a genotype fre-
quencynot different from the expectedMendelian ratio (TableS1).
SinceNpy6r are expressed in the testes, we investigated whether
deletion of this receptor impacts on fertility. Homozygous
Npy6r/ breeding pairs produced litters of a similar size to litters
fromWTandheterozygousbreedingpairs (TableS1). Additionally,
themortality rateandgender ratioofpupsborn fromheterozygous
and homozygous breeding pairs did not significantly differ from
that of WT (Table S1), further suggesting that disruption of Npy6r
expression does not have any impact upon reproductive fitness.
Lack of Npy6r Signaling Leads to an Early Reduction in
BodyWeight, Reduced LeanMass, and theDevelopment
of Late-Onset Obesity
Npy6r/ mice showed reduced body weights relative to WT
mice from 6 to 23 weeks of age but were no longer different atC24 weeks of age (Figure 1E). Npy6r/ mice showed markedly
reduced lean body mass when analyzed by whole-body dual-
energy X-ray absorptiometry (DXA) at 9, 15, 20, and 24 weeks
of age (Figure 1F). Importantly, lean body mass as a percent of
body weight was also lower in 20- and 24-week-old Npy6r/
mice compared toWTmice (Figure 1G), suggesting a dispropor-
tionate reduction in leanmass in the knockouts. Deletion ofNpy6r
also led to a transient reduction in absolute fat mass at 15 weeks
of age (Figure 1F), but at 20 or 24 weeks of age, Npy6r/ mice
showed greater adiposity (Figures 1F and IG). Consistent with
the DXA scan results, the absolute or relative weights of
dissected white adipose tissues depots from the inguinal (i),
epididymal (e), retroperitoneal (r), and mesenteric (m) sites and
the brown adipose tissue (b) were significantly reduced in the
absence of Npy6r in 15-week-old mice (Figures 1H and 1I). In
contrast to this reduction in adiposity at an early age, the weights
of dissected white and brown adipose tissue depots were mark-
edly greater in 24-week-old Npy6r/ mice (Figures 1J and 1K).
Since obesity is associated with ectopic lipid deposition in
various tissues including the liver, we investigated this in our
Npy6r/ mice. Interestingly, we found a significant increase in
liver weight relative to body weight inNpy6r/mice at 15 weeks
of age (Figure 1L). This was associated with a significantly
greater amount of lipid in the livers of these mice (Figure 1M),
as determined by oil red O staining (Figure 1O). Consistent
with this, 24-week-old Npy6r/mice also exhibited significantly
higher hepatic lipid accumulation (Figures 1N and 1P). Since
Npy6r/ mice showed reduced adiposity at 15 weeks of age
(Figures 1F, 1H, and 1I), this result suggests that ectopic fat
accumulation in the liver precedes the development of age-
induced fat accumulation in Npy6r/ mice.
Reduced Body Weight and Preferential Fat
Accumulation in Npy6r–/– Mice Are Associated with
Increased Cumulative Food Intake Relative to Body
Weight
To determine if the reduction in body weight and altered body
composition in Npy6r/ mice could be explained by changes
in feeding behavior, we analyzed the food intake of Npy6r/
and WT mice. Spontaneous food intake and spillage did not
differ significantly between genotypes at 15 weeks of age (Fig-
ure 2A). However, Npy6r/ mice exhibited a trend toward
increased daily food intake at 24 weeks of age (Figure 2B). In
spite of this, Npy6r/ mice displayed significantly greater fecal
output at 15, but not at 24, weeks of age (Figures S3A and S3B).
Following a 24 hr fast at 13 weeks of age, food intake, spillage
(Figure 2C), and fecal output (Figure S3C) were similar between
Npy6r/ and WT mice. Since food spillage was not significantly
different between Npy6r/ and WT mice, we also monitored
food intake as the amount of food removed from the hopper
over the entire period between 16 and 22 weeks of age and
found no significant difference in cumulative food consumption
(Figure 2D). Importantly, however, these differences were statis-
tically significant when normalized for body weight (Figure 2E),
indicating that increased food intake may contribute to the
increased adiposity and weight gain in older Npy6r/ mice.
Indirect calorimetry on 14-week-old Npy6r/mice revealed a
significant increase in energy expenditure compared to WT,
either when expressed as absolute values (Figure 2F) or whenell Metabolism 19, 58–72, January 7, 2014 ª2014 Elsevier Inc. 59
Figure 1. Chow-Fed Npy6r–/– Mice Exhibit Reduced Body Weight, Lean Mass, and Late-Onset Obesity
(A) Generation of the Npy6r-deficient mice.
(B) Genotyping was performed using GS(E)/GS(TE) or Neo(T)/GS(TE) primer pairs to amplify WT or knockout (Npy6r/) alleles, respectively.
(legend continued on next page)
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Npy6r/ mice exhibited significantly increased activity (Fig-
ure 2H). We further inquired if changes in resting metabolic
rate could also contribute to the observed increase in energy
expenditure in Npy6r/ mice by analyzing the energy expendi-
ture corresponding to the hour of least activity and found no sig-
nificant difference (Figures S4A and S4B; Table S2). In addition,
we assessed resting metabolic rate by extrapolating regression
lines of energy expenditure to physical activity (Zhang et al.,
2010) and found that resting energy expenditure is not signifi-
cantly different between 14-week-old Npy6r/ and WT mice
(Figures S4A and S4B; Table S2). These results indicate that
the absence of Npy6r signaling does not increase basal meta-
bolic rate, and that the increase in energy expenditure observed
in 14-week-old Npy6r/ mice was most likely due to the
increase in physical activity.
In addition to increased energy expenditure, 14-week-old
Npy6r/ mice demonstrated a significant elevation in respira-
tory exchange ratio (RER), indicative of a reduction in lipid utiliza-
tion for whole-body energy production (Figure 2I). While the
elevated RER in Npy6r/ mice may reflect the reduced
adiposity in 15-week-old Npy6r/ mice (Figures 1F and 1H),
an RER value greater than 1.0, as seen in Npy6r/ mice be-
tween 22:00 and 02:00 hr (Figure 2I), is associated with de
novo lipogenesis (Schutz, 2004). Since an increase in RER has
been demonstrated to predict weight gain (Marra et al., 2004;
Seidell et al., 1992; Weinsier et al., 1995), these data are in line
with the development of a late-onset increase in adiposity in
Npy6r/ mice.
Secondary to the age-induced increase in adiposity, 23-week-
old Npy6r/mice displayed a significant reduction in RER (Fig-
ure 2J), suggesting an increased preference for lipids as an
oxidative fuel source. Consistent with the increased energy
expenditure and physical activity seen in 14-week-old Npy6r/
mice, 23-week-old Npy6r/ showed significant increases in
energy expenditure when normalized for lean mass (Figures 2K
and 2L), as well as an increase in physical activity during the light
phase (Figure 2M). Furthermore, resting energy expenditure was
significantly higher in Npy6r/mice at 23 weeks of age (Figures
S4C and S4D; Table S2). These data suggest that, in addition to
increased physical activity, an increase in basal metabolic rate is
an important contributor to the increased total energy expendi-
ture observed in 23-week-old Npy6r/ mice.
Npy6r Signaling Is Critical for Maintaining Glucose
Homeostasis in Mice
Skeletal muscle is a major site of insulin-mediated glucose
disposal, and a reduction in lean mass is associated with impair-
ment in glucose homeostasis and insulin sensitivity (Dulloo,(C) Npy6r mRNA expression was determined in various tissues, including the h
GAPDH as a housekeeping gene.
(D) A representative photograph of 15-week-old WT and Npy6r/ mice.
(E) Body weight in Npy6r/ and WT mice was measured on a weekly basis.
(F and G) Body composition (lean and fat mass) was determined by DXA and no
(H–K) Absolute and relative (as a percent of body weight) weights of white adipose
(r) sites, and intrascapular brown adipose tissue (b) depots were measured in 15
(L–N) (L) Liver weight and (M and N) liver morphology were determined by the qu
(O and P) Representative oil red O-stained liver sections fromWT and Npy6r/m
and Table S1.
C2009). Since Npy6r/ mice demonstrated a significant reduc-
tion in lean body mass, we suspected that glucose metabolism
might be impaired in these mice. Interestingly, 15-week-old
Npy6r/ mice exhibited normoglycemia under fasted and
nonfasted conditions (Figure 3A). Despite this, Npy6r/ mice
at 15 weeks of age exhibited reduced serum insulin concentra-
tions, significantly so in the nonfasted condition (Figure 3B), sug-
gesting improved insulin action on glucose clearance. Indeed, in
response to i.p. glucose administration, the area under the curve
for the glucose tolerance tests were significantly reduced in
15-week-old Npy6r/ mice (Figures 3C and 3D) despite signifi-
cantly lower serum insulin concentrations (Figure 3E).
In contrast, while fasted and nonfasted blood glucose levels
were similar between 24-week-old Npy6r/ and WT mice (Fig-
ure 3F), the heightened fat accumulation in Npy6r/ mice of
this age is accompanied by a significant elevation in nonfasting
serum insulin concentrations (Figure 3G), suggesting decreased
insulin action in older Npy6r/ mice. Consistent with this, we
found that insulin signaling in muscle and liver, as determined
by Akt phosphorylation, is reduced in 24-week-old Npy6r/
mice (Figures S5A and S5B). Despite this, Npy6r deficiency did
not result in deterioration in glucose tolerance, with blood
glucose and serum insulin levels in response to i.p. glucose injec-
tion being similar between 24-week-old Npy6r/ and WT mice
(Figures 3H and 3I).
Npy6r–/– Mice Show Exacerbated Diet-Induced Obesity
We next assessed the effect of Npy6r deletion in mice on a high-
fat diet (HFD), which was introduced at 7 weeks of age and
continued for 16 weeks. Relative toWT,Npy6r/mice exhibited
significantly lower starting body weights (Figure 4A) but
displayed significantly greater relative body weight gain on the
HFD (Figure 4B). Importantly, after 8 weeks on the HFD (i.e.,
15 weeks of age) Npy6r/ mice showed similar body weights
to age-matched WT controls (Figure 4A), showing that the
normalization of body weight in 24-week-old chow-fed Npy6r/
mice seen in Figure 1E was accelerated by the obesogenic diet.
Consistent with the effect of Npy6r deletion in mice on a
normal chow diet (Figures 1F and 1G), HFD-fed Npy6r/ mice
displayed reduced lean body mass as determined by whole-
body DXA scans and when expressed as either absolute weight
or as a percent of body weight (Figures 4C and 4D). Npy6r/
mice also showed significantly higher adiposity at 7 and
14 weeks after the commencement of HFD feeding (Figures 4C
and 4D). This greater adiposity was confirmed by significantly
greater absolute and relative masses of dissected white and
brown adipose tissue depots in Npy6r/ mice after 16 weeks
on the HFD (Figures 4E and 4F). These data show that, together
with the suppression of lean body mass, the impact of Npy6rypothalamus, testes, and inguinal white adipose tissue (i), by RT-PCR using
rmalized to body weight at indicated time points in Npy6r/ and WT mice.
tissues from the inguinal (i), epidydimal (e), mesenteric (m), and retroperitoneal
- and 24-week-old Npy6r/ and WT mice.
antity of oil red O staining from 15- and 24-week-old Npy6r/ and WT mice.
ice. Data are means ±SEM of 5–13 mice per group. See also Figures S1 and S2
ell Metabolism 19, 58–72, January 7, 2014 ª2014 Elsevier Inc. 61
(legend on next page)
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Figure 3. Impact of Npy6r Deletion on Glucose Homeostasis in Mice
(A and B) Fasted and nonfasted blood glucose and serum insulin levels in 15- and (F and G) 24-week-old Npy6r/ andWTmice were determined. (C–E) Fifteen-
and (H and I) 24-week-old Npy6r/ and WT mice were fasted, and glucose tolerance tests (1 mg/kg) were performed. Blood glucose and corresponding serum
insulin levels were assessed at indicated time points in these mice. Results are means ±SEM of 5–11 mice per group. See also Figure S5.
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the HFD.
Interestingly, the exacerbated body weight gain and adipose
tissue accumulation in Npy6r/ mice on a HFD occurred in
the presence of transient hyperphagia. While food intake in ab-
solute weight did not differ significantly between genotypes at
3 weeks after the introduction of HFD (Figure 4G), Npy6r/
mice consumed significantly more HFD relative to their body
weights compared to WT controls at this time point (Figure 4H).
In contrast, food intake of Npy6r/ mice was significantly
reduced after 13 weeks on the HFD (Figures 4G and 4H). Reflec-Figure 2. Altered Food Intake and Energy Homeostasis in Npy6r-Defic
(A–C) Daily and 24 hr fasting-induced food intake and spillage were assessed in
(D and E) Cumulative food consumption from 16- to 22-week-old Npy6r/ and
(F–M) Light and dark cycle energy expenditure (normalized to total lean mass),
metabolic chambers during indirect calorimetry studies in 14- and 23-week-old
indicated by J. Data are means ±SEM of five to nine mice per group. See also F
Ctive of the changes in absolute food consumption (Figure 4G),
fecal output was significantly reduced after 10 but not 3 weeks
of high-fat feeding in Npy6r/ mice (Figure S3D). In response
to a 24 hr fast, young Npy6r/ mice exhibited no change in
food intake (Figures 4I and 4J) or fecal output (Figure S3E),
whereas older knockouts demonstrated a significant reduction
in fasting-induced food intake (Figures 4K and 4L) and fecal
output (Figure S3F). The transient increase in nonfasted food
intake relative to body weight seen at 3 weeks after the provi-
sion of HFD (Figure 4H) may contribute to the accelerated
body weight gain in HFD-fed Npy6r/ mice. Additionally, sinceient Mice
Npy6r/ and WT mice at indicated time points.
WT mice were recorded and normalized to total body weight.
ambulatory activity, and respiratory exchange ratio (RER) were determined in
Npy6r/ and WT mice. Significant time and genotype interaction effects are
igures S3 and S4 and Table S2.
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Figure 4. Mice Lacking Npy6r Showed Exacerbated Diet-Induced Obesity
(A and B) Seven-week-old Npy6r/ and WT mice underwent high-fat feeding for 16 weeks, and body weight was monitored on a weekly basis.
(C and D) Body composition (lean and fat mass) was determined by DXA and subsequently normalized to body weight.
(E and F) Weight of white adipose tissues from the inguinal (i), epidydimal (e), mesenteric (m), and retroperitoneal (r) sites, and intrascapular brown adipose tissue
(b) depots in high-fat-fed Npy6r/ and WT mice were measured and expressed as absolute weight or as a percentage of body weight.
(G and H) Daily food intake in high-fat-fed Npy6r/ and WT mice was recorded.
(I–L) Mice were fasted for 24 hr, and fasting-induced food intake was determined at indicated time points. Food intake results were expressed in absolute terms or
as a percentage of body weight.
(legend continued on next page)
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Figure 5. Npy6r Deficiency Is Associated with Reduced Vip
Expression in the SCN
(A) Representative photographs of coronal brains sections showing the
distribution of Npy6r as indicated by lacZ expression in the mouse SCN.
(B and C) Representative photographs showing coexpression of lacZ and Vip
mRNA in neurons of the SCN of Npy6r/ mice.
(D and E) Representative photographs showing the absence of lacZ and
arginine vasopressin (AVP) colocalization in the suprachiasmatic nucleus
(SCN) of Npy6r/ mice. Light green and dark blue arrows denote neurons
expressing only AVP and only lacZ, respectively. See also Figure S6.
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were significantly reduced, lack of Npy6r in mice may lead to
increased feeding efficacy and greater body weight gain seen
in HFD-fed Npy6r/ mice.
Using indirect calorimetry we identified that after 14 weeks on
theHFD,Npy6r/mice did not exhibit any difference in absolute
energy expenditure (Figure 4M). When adjusted for the differ-
ence in lean body mass, however, energy expenditure was
significantly greater in HFD-fed Npy6r/ mice (Figure 4N). This
increase in energy expenditure was more pronounced than
that seen in chow-fed Npy6r/ mice at either the younger age
or the older age (Figures 2G and 2L). Unlike in chow-fed animals(M–P) After 12 weeks of high-fat feeding, energy expenditure, ambulatory activit
(Q and R) Fasted and nonfasted blood glucose and serum insulin levels were de
(S and T) Mice were fasted for 6 hr and injected with glucose (1 mg/kg). Blood glu
Data are means ±SEM of nine males per group. See also Figure S3.
C(Figure 2H–2J and 2M), we did not detect any significant differ-
ences in physical activity (Figure 4O) or RER (Figure 4P) between
HFD-fed Npy6r/ and WT mice. These results show that the
increase in body weight gain and fat accumulation in Npy6r/
mice on the HFD is not due to reduced metabolism.
Interestingly, after 12 weeks on the HFD, Npy6r/ mice still
displayed normoglycemia (Figure 4Q) but showed elevated
serum insulin levels, significantly so in the nonfasted state (Fig-
ure 4R). However, when assessed for glucose tolerance,
Npy6r/mice on HFD displayed markedly higher blood glucose
(Figure 4S) and serum insulin levels (Figure 4T) in response to i.p.
glucose injection, signifying impaired glucose metabolism.
Taken together, our data demonstrate that deficiency in Npy6r
in mice exacerbates diet-induced obesity and promotes the
associated abnormalities in glucose homeostasis.
Npy6r–/– Mice Have Impaired Central VIP Signaling in
Association with Reduced Serum IGF-1 and Blunted
Corticosterone Rhythm
In order to identify the underlying mechanism that leads to the
altered metabolic phenotype of Npy6r deficiency, we focused
on areas of highest Npy6r expression. As shown in Figures 5A,
S1, and S2, the strongest expression of Npy6r was found in
the hypothalamic SCN, with expression also detected in the
testes. It is known that reduction in circulating testosterone
levels is strongly linked to reduced lean body mass (Sattler
et al., 2009) and obesity (Nettleship et al., 2007). However,
Npy6r/ mice did not show reduced serum testosterone levels
(Figure S6A), suggesting that this is not a major contributor to the
observed phenotype.
In order to elucidate possible pathways by which Npy6r
signaling may regulate energy balance and body composition,
we determined the molecular identity of Npy6r-expressing neu-
rons in the SCN by utilizing the introduced lacZ gene into the
Npy6r gene coding region to visualize the expression pattern
of Npy6r by staining for b-gal. Immunostaining with antibodies
against a variety of neuropeptides known to be expressed in
the SCN (Reghunandanan et al., 1993) revealed vasoactive in-
testinal peptide (VIP) as colocalized with the Npy6r (Figures
S6B and S6C). To further confirm this colocalization, we per-
formed in situ hybridization for Vip mRNA on SCN sections pre-
viously stained for LacZ. As shown in Figures 5B and 5C, almost
all LacZ-positive neurons express VIP, shown in the overlaying
silver grains. In contrast, immunostaining using arginine vaso-
pressin (AVP) antibody did not show any overlap in expression
with Npy6r-positive neurons (Figures 5D and 5E).
PP Is the Endogenous High-Affinity Ligand for the Npy6r
in Mice
The SCN receives input from a variety of areas in the brain (Welsh
et al., 2010). Additionally, the SCN is accessible to factors
derived from the circulation (Welsh et al., 2010), including periph-
erally derived PP and PYY. To investigate which Y-receptor
ligand is the most effective transducer of Npy6r function in vivo,y, and respiratory exchange ratio (RER) were determined.
termined.
cose and corresponding insulin levels at indicated time points were assessed.
ell Metabolism 19, 58–72, January 7, 2014 ª2014 Elsevier Inc. 65
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WT mice in response to i.p. administration of either PP, PYY,
PYY3-36, or saline. Injection of PYY or PYY3-36 into WT mice
did not induce any significant differences in Fos expression in
the SCN compared to saline controls (Figure 6A) but significantly
increased Fos expression in other areas like the arcuate nucleus
(ARC) (data not shown). Importantly, a significant increase in Fos
immunoreactivity in the SCN of WT mice was seen following i.p.
PP injection, and this effect was absent in Npy6r/ mice (Fig-
ures 6A and 6B). To further confirm this, we performed radioli-
gand-binding assays on brain sections from WT and Npy6r/
mice using I125-labeled PP. Supporting the notion that PP is a
physiological activator ofNpy6r, I125-labeled PP binding was de-
tected in the SCN of WTmice, but not inNpy6r/ brain sections
(Figure S7A). By contrast, the binding of I125-labeled PP was not
observed in WT brain slices cotreated with human PP (Fig-
ure S7A). This raises the possibility that increases in circulating
PP levels due to food intake or hypoglycemia can trigger
Npy6r-mediated events in the SCN.
Previous studies have shown that extracellular signal-related
kinase (ERK) is involved in mediating downstream signaling of
Y receptors, including the Npy1r (Shi et al., 2013). To investigate
whether ERK may also act as a downstream substrate for the
Npy6r in response to PP, we injected WT and Npy6r/ mice
with either saline or PP and assessed ERK phosphorylation
(p-ERK) by immunohistochemistry. While PP-induced p-ERK in
the SCN region was elevated in WT mice compared to saline-
injected controls, induction of pERK was strongly reduced in
the SCN of Npy6r/ mice in response to PP (Figure 6C). Taken
together, these results are in keeping with the notion that PP is a
physiological ligand for Npy6r and that ERK is an important
downstream substrate for Npy6r signaling.
Strong evidence exists that PP regulates energy homeostasis
by decreasing food intake and increasing energy expenditure via
action on Ppyr1 (Lin et al., 2009). Our findings that PP also acti-
vates the Npy6r raised the possibility that PP could regulate
energy balance and appetite separately via an Npy6r signaling
pathway. To examine this directly, both WT and Npy6r/ mice
were given an i.p. injection of saline or PP at 7 a.m. and 7 p.m.,
with subsequent monitoring of oxygen consumption, energy
expenditure, and fasting-induced food intake. Consistent with
previous studies, we found that oxygen consumption and energy
expenditure were significantly increased in WTmice in response
to PP injection (Figures 6D and 6E). However, these differences
were not noted in Npy6r/mice (Figures 6D and 6E), indicating
that Npy6r is required to mediate the effects of PP in the regula-
tion of energy expenditure. In response to PP, both WT and
Npy6r/ mice exhibited reductions in fasting-induced food
intake compared to the corresponding saline group, significantly
so in WT animals (Figures 6F and 6G). However, the degree to
which PP suppressed food intake was significantly less in
Npy6r/ mice at an early time point (0–4 hr), and these differ-
ences were even greater when normalized for body weight (Fig-
ures 6F and 6G).
PP-Mediated Npy6r Signaling Controls Vip Expression
in the SCN
Having established that Npy6r are coexpressed with VIP in
neurons of the SCN, we hypothesized that the metabolic pheno-66 Cell Metabolism 19, 58–72, January 7, 2014 ª2014 Elsevier Inc.type ofNpy6r/micemay be explained by impairment in down-
stream actions of VIP. We determined Vip mRNA levels in the
hypothalamus of WT and Npy6r/ mice by quantitative real-
time PCR. Consistent with our hypothesis of impaired VIP
signaling, we found that Vip expression was significantly
reduced in the hypothalamus of Npy6r/ (Figure 7A), but not
in other peripheral tissues such as colon, small intestine, or
pancreas (Figure S7B). Lack of change in peripheral Vip mRNA
levels is consistent with unaltered serum VIP levels in Npy6r/
mice (Figure S7C). Additionally, Vip expression levels in the
SCN of Npy6r/ were significantly reduced as determined by
in situ hybridization (Figures 7B and 7C), confirming that VIP
signaling is disrupted in the SCN of Npy6r/ mice.
VIP is known as a key regulator of the growth hormone (GH)
axis (Asnicar et al., 2002; Niewiadomski et al., 2008), circadian
rhythm (Aton et al., 2005; Brown et al., 2007; Pantazopoulos
et al., 2010; Piggins and Cutler, 2003), and glucocorticoid secre-
tion (Loh et al., 2008). Previous studies showed that VIP-deficient
mice exhibit reduced IGF-1 levels (Asnicar et al., 2002; Niewia-
domski et al., 2008), and perturbation in the GH/IGF-1 axis is
associated with dwarfism and increased adiposity in rodents
and humans (Lichanska and Waters, 2008). We thus hypothe-
sized that the GH/IGF-1 axis is perturbed in Npy6r/ mice and
that this contributes to the development of reduced lean mass
and late-onset obesity. Indeed, Npy6r/ mice showed signifi-
cantly reduced serum IGF-1 levels (Figure 7D), coinciding with
a reduction in hypothalamic expression of growth hormone
releasing hormone (Ghrh) (Figure 7E). Additionally, loss of
Npy6r in mice led to blunted diurnal variations in serum cortico-
sterone levels (Figure 7F). Importantly, the damped cortico-
sterone rhythm seen in Npy6r/ mice is not due to impaired
secretion, since a 24 hr fast elicited comparable increases in
corticosterone levels in mice of both genotypes, although
Npy6r/ mice showed significantly reduced corticosterone
levels compared to WT controls under both fed and fasted con-
ditions (Figure 7G). Since timing of food intake is linked to corti-
costerone secretion (Sheward et al., 2007) and has been shown
to be abrogated in mice with disrupted VIP signaling (Bechtold
et al., 2008), we investigated food consumption during light
and dark phases and found significantly reduced daytime
feeding in Npy6r/ mice (Figures 7H and 7I). Hence, our data
provide evidence that the reduced lean mass and late-onset or
diet-induced increases in adiposity in mice lacking Npy6r may
result from reduced hypothalamic Ghrh expression and circu-
lating IGF-1 levels, potentially attributable to impairment in VIP
signaling in the SCN.
Further evidence supporting the notion of a PP-controlled GH/
IGF-1 axis comes from experiments in which we injected PP via
the i.c.v. route and measured the consequences on Ghrh
mRNA expression in WT compared to Npy6r/ mice. While
i.c.v. administration of PP toWTmice led to a significant increase
in Ghrh mRNA levels in the ARC, this PP-dependent effect was
absent in Npy6r/ mice (Figures 7J and 7K). Together with our
findings of SCN-specific Npy6r expression, colocalization of
Npy6r with VIP in the SCN, reduced expression of Vip mRNA in
the SCN of Npy6r/ mice, and PP-induced Fos activation in
the SCN, these data indicate that alterations in GH/IGF-1 axis
activity in Npy6r/ mice are a direct consequence of the lack
of PP-induced activation of Npy6r in the SCN, possibly via VIP.
Figure 6. Pancreatic Polypeptide Is the Endogenous Ligand for the Npy6r In Vivo
(A and B)WT andNpy6r/mice were injectedwith either saline, PP (200 mg/kg), PYY (200 mg/kg), or PYY 3-36 (200 mg/kg). Fos expression in the suprachiasmatic
nucleus (SCN) of the hypothalamus was assessed by immunohistochemistry after 30 min injection. Fos-positive neurons in SCN brain sections were quantified.
(C) WT and Npy6r/ mice were injected with either saline or PP, and PFA perfused brains were extracted and processed for immunohistochemistry with
antibodies to p-ERK.
(D and E)WT andNpy6r/mice were injectedwith either saline or PP (300 mg/kg) as indicated, and oxygen consumption and energy expenditure weremonitored
by indirect calorimetry.
(F and G) WT and Npy6r/ mice were fasted for 24 hr, and prior to food being given mice were injected with either saline or PP (300 mg/kg) as indicated.
Fasting-induced food intake was determined for a period of 24 hr. Data are means ±SEM of three to six mice per group. See also Figure S7.
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signaling are linked to the observed changes in energy homeo-
stasis such as the reduction of IGF-1 levels, we delivered
VIP(6-28), a VPAC receptors antagonist, via the i.c.v. route to
WT andNpy6r/mice, followed 5min later by i.p. administration
of PP. Analysis of serum samples collected 30 min following PP
injection revealed that blockade of VPAC receptors in WT mice
completely prevented the PP-induced increase in serum IGF-1
in WT mice (Figure 7L). Furthermore, the effect of PP to raise
serum IGF-1 was totally absent in Npy6r/ mice (Figure 7L),
clearly demonstrating involvement of Npy6r signaling via VIP in
controlling the growth hormone axis.
DISCUSSION
In this study, we demonstrate that Npy6r signaling in the SCN is
critical in the regulation of energy homeostasis. Our results show
that body weight, body composition, metabolic rate, and activity
of the hypothalamo-pituitary-somatotrophic axis are signifi-
cantly influenced by Npy6r signaling in mice, since lack of
Npy6r leads to reduced lean mass and increased energy expen-
diture that are accompanied by significant improvements in
glucose homeostasis and reduced hypothalamic Ghrh mRNA
expression and circulating IGF-1 levels. Interestingly, Npy6r-
deficient mice develop late-onset obesity, and this is further
exacerbated when mice are fed a high-fat diet. Additionally, we
demonstrate that PP is an endogenous high-affinity ligand for
Npy6r in mice, since exogenous administration of PP, but not
PYY or PYY3-36, activated Npy6r-expressing neurons in the
SCN, and this effect was absent in Npy6r-deficient mice. The
mechanism by which Npy6r mediates its effects on the GH
axis and energy homeostasis is most likely through alterations
in VIP signaling in the hypothalamus. This is demonstrated by
the strong overlap in expression of Vip and Npy6r within the
SCN, the brain region to which the Npy6r is confined, and
the significant reduction in Vip expression in this nucleus in the
absence of Npy6r signaling. Moreover, the fact that i.p. PP injec-
tion increases energy expenditure and decreases food intake,
hypothalamic Ghrh mRNA expression, and circulating IGF-1
levels in WT but not in Npy6r/ mice, and that the effect on
IGF-1 is blocked by prior administration of a VPAC receptors
antagonist, strongly supports this stand.
It has been documented that the SCN contains the master
circadian clock in mammals; it generates distinct temporal
changes in biological processes such as core body temperature
and hormone secretion (Huang et al., 2011). Disruptions in circa-
dian rhythm, whether by genetic or environmental influences,
can result in metabolic dysfunction (Huang et al., 2011). For
instance, mutation of either of two key regulators of the circadian
cycle, circadian locomotor output cycles kaput (CLOCK) or brainFigure 7. Pancreatic Polypeptide-Mediated Npy6r Signaling Controls V
(A–C) (A) Vip mRNA expression in the hypothalamus and (B and C) in SCN of Np
(D and E) Fasted serum IGF-1 and hypothalamic Ghrh mRNA expression were d
(F and G) Serum corticosterone levels were assessed at intervals of 6 hr or unde
(H and I) Light- and dark-phase food intake was measured for 6 consecutive day
(J and K) Npy6r/ and WT mice were injected with either saline or PP, and Ghrh
(L) Npy6r/ and WT mice were injected with either saline, PP, or PP and VIP rec
IGF-1 ELISA kit. Data are means ±SEM of four to eight mice per group. See also
Cand muscle aryl hydrocarbon receptor nuclear translocator
(ARNT)-like 1 (BMAL1), not only disrupt normal circadian rhythm,
manifesting in loss of normal daily hormonal and feeding pat-
terns, but also predispose mice to metabolic diseases (Mar-
cheva et al., 2010; Rudic et al., 2004; Turek et al., 2005). VIP is
a critical regulator of circadian rhythm in the SCN, with deletion
of VIP or its receptor, VPAC2, leading to loss of circadian rhyth-
micity and synchrony in SCN neurons (Aton et al., 2005; Hannibal
et al., 2011; Harmar et al., 2004). Since our studies demonstrate
that hypothalamic VIP expression is reduced in Npy6r-deficient
mice, it is possible that the impaired circadian rhythm observed
in our Npy6r/mice, as evidenced by blunted daily fluctuations
in serum corticosterone levels and reduced light-phase feeding,
may be due to impaired VIP signaling, and therefore could
contribute to the development of metabolic abnormalities in
these mice.
In addition to regulating circadian rhythm, VIP is an important
regulator of the GH axis. VIP is known to stimulate GH release in
rats in vivo (Bluet-Pajot et al., 1987), in cultured bovine adenohy-
pophysial cells (Soliman et al., 1995), and in perifused bovine
adenohypophysis (Hashizume and Kanematsu, 1990). More-
over, loss of VIP or VPAC2 in mice leads to reduced growth in
association with reduced circulating IGF-1 levels (Asnicar
et al., 2002; Niewiadomski et al., 2008). Indeed, we demonstrate
that blockade of VPAC abolishes the Npy6r-mediated alteration
of circulating IGF-1 levels. This finding, combined with our
observations of reduced SCN Vip mRNA expression and
reduced GH/IGF-1 axis activity in our Npy6r/ mice, suggests
that the reduced lean mass and late onset obesity observed in
the absence of Npy6r signaling are due to perturbations in
normal VIP regulation of the GH/IGF-1 axis. Consistent with
known effects of reduced circulating IGF-1 levels in inducing
obesity (Rosen et al., 2004), our data suggest that the lower
circulating IGF-1 levels could account for the decreased lean
mass and the increased relative adiposity in Npy6r/ mice.
Thus, impairment in function of the GH/IGF-1 axis, as well as
impaired circadian rhythmicity resulting from defects in VIP
neuronal signaling pathways in the SCN, could have contributed
to the reduction in lean body mass and the development of late-
onset obesity in Npy6r/ mice.
In this study, PP was found to be the only high-affinity ligand
that can trigger significant elevation of Fos expression in the
SCN in WT compared to Npy6r/ mice. PP is released from
pancreatic F cells in response to stimuli such as food intake
and hypoglycemia, mainly by vagal muscarinic activation (Havel
et al., 1993). Previously it was thought to be a ligand only for the
Ppyr1, triggering responses in the brain stem and ARC to inhibit
food intake (Lin et al., 2009) and enhance digestive events such
as gastric secretion, motility, and emptying by subsequent acti-
vation of vagal cholinergic pathways (McTigue et al., 1997). LackIP Expression in the SCN
y6r/ mice and WT controls.
etermined in chow-fed Npy6r/ and WT mice.
r fasted condition in Npy6r/ mice and WT controls.
s in 16- and 23-week-old Npy6r/ and WT mice.
mRNA levels in ARC were assessed.
eptor antagonist. Subsequently, serum IGF-1 levels were determined by using
Figure S7.
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mass on a lean background, and attenuation of certain aspects
of the obesity syndrome and enhanced fertility on a background
of leptin deficiency (Sainsbury et al., 2002b; Zhang et al., 2010).
However, satiety regulation of PP via Ppyr1 signaling seems
to be mainly confined to the ARC in the hypothalamus, particu-
larly to neurons that coexpress alpha melanocyte stimulating
hormone (a-MSH) (Lin et al., 2009). It is possible that the
reduced body weight or attenuated obesity syndrome of
Ppyr1/mice was mediated by the high circulating PP concen-
trations seen in these mice, acting on other Y receptors besides
Ppyr1, such as the herein-identified Npy6r. In support of this, PP
transgenic mice, which have a 20-fold increase in plasma PP
levels, have a similar metabolic phenotype to Ppyr1/ mice
(Ueno et al., 1999). Our current data extend these findings to
suggest that the late-onset obesity phenotype of our Npy6r/
mice could be mediated by lack of action of PP on Npy6r in
the SCN.
In summary, our study demonstrates that Npy6r is a critical
regulator of energy homeostasis and body composition, with
germline deletion of Npy6r leading to reduced body weight,
inhibition of lean body mass, and an age-dependent increase
in adiposity that is exacerbated by high-fat feeding, with these
effects likely mediated via the lack of Npy6r signaling in the
SCN to influence the VIP-GH/IGF-1 axis. Future studies in
mice into the function and possible clinical utility of Y receptors
and their ligands as drug targets must therefore take into
account this new knowledge that Npy6r plays an important
role in the regulation of energy homeostasis.
EXPERIMENTAL PROCEDURES
Animals
All animal care and experiments were approved by the Garvan/St. Vincent’s
Animal Ethics Committee. Npy6r/ mice were generated and genotyped
as described in Supplemental Experimental Procedures. Male mice on a
mixed C57BL/6–129SvJ background were used for all experiments, except
where noted. Mice were housed under a controlled temperature of
22C and a 12 hr light cycle (lights on from 07:00 to 19:00 hr) with ad
libitum access to water and a standard chow diet (6% calories from fat,
21% calories from protein, 71% calories from carbohydrate, 2.6 kcal/g,
Gordon’s Specialty Stock Feeds, Australia) or fed a HFD (43% kilojoules
from fat, 17% kilojoules from protein, 40% kilojoules from carbohydrate,
4.8 kcal/g, Specialty Feeds, Australia) for 16 weeks starting from 7–8 weeks
of age.
RNA Extraction and Quantitative Real-Time PCR
Hypothalami were dissected and immediately frozen in liquid N2, and RNAwas
extracted using Trizol Reagent (Sigma, St. Louis, MO) and processed
for quantitative real-time PCR with the Light-Cycler 480 Real-Time PCR
system (Roche, Switzerland) as described in the Supplemental Experimental
Procedures.
Metabolic Measurements and Body Composition
Weekly body weight was determined from 6 weeks of age onward, unless
otherwise stated. Food intake and fecal output were examined in chow- and
high-fat-fed mice under normal and fasting states as described in the Supple-
mental Experimental Procedures. Whole-body lean and fat masses were
determined by DXA (Lunar Piximus II mouse densitometer; GE Healthcare,
UK) as previously described (Baldock et al., 2009; Zhang et al., 2010). VO2,
energy expenditure, RER, and physical activity were assessed using an indi-
rect calorimeter (Oxymax series; Columbus Instruments, Columbus, OH) as
described in the Supplemental Experimental Procedures.70 Cell Metabolism 19, 58–72, January 7, 2014 ª2014 Elsevier Inc.Glucose Tolerance Tests and Serum Assays
Mice were fasted for 16–18 hr and i.p. administered with glucose (1 mg/kg
body weight). Blood glucose levels were assessed at 0, 15, 30, 60, and
90 min after glucose administration using an Accu-chek Go glucometer
(Roche, Dee Why, Australia). Serum was collected and stored for subsequent
insulin assay. Serum insulin, testosterone, IGF-1, VIP, and corticosterone
levels were measured in accordance with the manufacturers’ specifications
as described in the Supplemental Experimental Procedures.
Oil Red O and b-Galactosidase Staining
Frozen livers sections (6 mm) were cut on a cryostat, mounted on slides, and
processed for oil red O staining as described in the Supplemental Experi-
mental Procedures. Coronal brain and peripheral tissue frozen sections
(25 mm) were mounted on slides and processed for b-galactosidase histo-
chemistry as described in the Supplemental Experimental Procedures.
Immunohistochemistry
Animals were anesthetized, and the brains were perfused with saline and then
4% paraformaldehyde (PFA). Brains were postfixed in 4% PFA, then placed in
30% sucrose overnight and cut at 35 mm on a cryostat. Subsequently, immu-
nohistochemistry was performed using antibodies against Fos, p-ERK, VIP, or
AVP. Fos expression was visualized in brain sections containing the SCN
(Bregma 0.34 mm through to 0.70 mm) (Franklin and Paxinos, 1997) with
a light microscope (Leica, Heerbrugg, Switzerland). The number of Fos-
positive neurons within a constant and defined frame was counted using
ImageJ64 software (National Institutes of Health).
In Situ Hybridization and Colocalization Study
Coronal brain sections (30 mm) were cut on a cryostat and mounted on slides.
Matching sections from the same coronal brain level from different groups of
mice were examined together using radiolabeled DNA oligonucleotides com-
plementary to mouse Vip and Ghrh. Sequence of probes and details of the
in situ hydridization methodology can be found in the Supplemental Experi-
mental Procedures. For colocalization of Npy6r and Vip study, coronal brain
section were first processed for b-gal staining, then followed by in situ hydrid-
ization as described in the Supplemental Experimental Procedures. Slides
were visualized and imaged with a light microscope (Leica, Heerbrugg,
Switzerland).
Stereotaxic Brain Delivery of Peptides
Adult mice were anaesthetized and placed on a Kopf stereotaxic frame (David
Kopf Instruments, Tujunga, CA, USA). A total of 1 ml PP or 1.5 ml VPAC2
antagonist (2 mg/ul) was injected into the lateral ventricle at a rate of 0.1 mL/min
using a 10 ml Hamilton syringe attached to Micro4 Micro Syringe
Pump Controller (World Precision Instruments Inc., Sarasota). The injection
coordinates were (from bregma) as follows: anteroposterior, –0.34 mm;
mediolateral, ±1.00 mm; and dorsoventral, –2.5 mm (Franklin and Paxinos,
1997). Animals were kept on a heating pad during surgery.
Statistical Analyses
All data are expressed as mean ±SEM. A two-tailed Student’s t test was used
to test the difference between two groups of mice. Differences among groups
of mice were assessed by two-way ANOVA or repeated-measures ANOVA.
Bonferroni post hoc tests were performed to identify differences among
means. Statistical analyses were assessed using Prism software (GraphPad
Software, Inc, LaJolla). Differences were regarded as statistically significant
if p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article at http://
dx.doi.org/10.1016/j.cmet.2013.11.019.
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